Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized and released by the pineal gland following a circadian rhythm characterized by high levels during the night. It shows several pharmacological effects on diverse cellular and animal models, mainly related to either its antioxidant activity or to its ability to activate specific receptors (MTr). Melatonin is widely used as a self-administered food additive, but its therapeutic potential needs more investigation and is hampered by its poor pharmacokinetics. This review will focus on the medicinal chemistry of agonist ligands of the two human GPCRs MT1 and MT2 melatonin receptors. The recent introduction of ramelteon, a non-selective MT1/MT2 agonist for the treatment of insomnia, and the advancement to clinical trials of other MTr agonists have renewed interest for different classes of compounds endowed with this activity. Several chemical classes of MTr agonists are described in the literature, generally characterized by an indole, or an indole bioisostere, carrying an amide side chain and a methoxy group, or substituents with similar stereoelectronic features. Abundant information is available for nonselective MT1/MT2 ligands, and several molecular models, both ligand- and receptor-based, have been proposed to rationalize their structure activity relationships. Fewer classes of selective agonists have been reported in the literature, and they could help clarifying the physiological role of the two receptor subtypes. A brief discussion on the therapeutic potential of this class of compounds is based on the clinical data available for the agonists ramelteon, agomelatine, β- methyl-6-chloromelatonin (TIK-301) and VEC-162.
Current Topics in Medicinal Chemistry
Title: Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Volume: 8 Issue: 11
Author(s): Silvia Rivara, Marco Mor, Annalida Bedini, Gilberto Spadoni and Giorgio Tarzia
Affiliation:
Abstract: Melatonin (N-acetyl-5-methoxytryptamine) is synthesized and released by the pineal gland following a circadian rhythm characterized by high levels during the night. It shows several pharmacological effects on diverse cellular and animal models, mainly related to either its antioxidant activity or to its ability to activate specific receptors (MTr). Melatonin is widely used as a self-administered food additive, but its therapeutic potential needs more investigation and is hampered by its poor pharmacokinetics. This review will focus on the medicinal chemistry of agonist ligands of the two human GPCRs MT1 and MT2 melatonin receptors. The recent introduction of ramelteon, a non-selective MT1/MT2 agonist for the treatment of insomnia, and the advancement to clinical trials of other MTr agonists have renewed interest for different classes of compounds endowed with this activity. Several chemical classes of MTr agonists are described in the literature, generally characterized by an indole, or an indole bioisostere, carrying an amide side chain and a methoxy group, or substituents with similar stereoelectronic features. Abundant information is available for nonselective MT1/MT2 ligands, and several molecular models, both ligand- and receptor-based, have been proposed to rationalize their structure activity relationships. Fewer classes of selective agonists have been reported in the literature, and they could help clarifying the physiological role of the two receptor subtypes. A brief discussion on the therapeutic potential of this class of compounds is based on the clinical data available for the agonists ramelteon, agomelatine, β- methyl-6-chloromelatonin (TIK-301) and VEC-162.
Export Options
About this article
Cite this article as:
Rivara Silvia, Mor Marco, Bedini Annalida, Spadoni Gilberto and Tarzia Giorgio, Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders, Current Topics in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/156802608784936719
DOI https://dx.doi.org/10.2174/156802608784936719 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Minoxidil Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders
Current Drug Metabolism Cardiac and Renal Nitric Oxide in the Adaptation to Hypovolemic Shock
Current Enzyme Inhibition Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Metabolic Fate of Endocannabinoids
Current Neuropharmacology Quinazolin-4-One: A Varsatile Molecule
Current Bioactive Compounds Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends
Current Vascular Pharmacology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety Contribution and Value of Biomarkers in Acute Aortic Syndromes
Current Pharmaceutical Biotechnology New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials